247 related articles for article (PubMed ID: 33099868)
1. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
[TBL] [Abstract][Full Text] [Related]
2. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF
Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920
[TBL] [Abstract][Full Text] [Related]
3. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
4. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
[TBL] [Abstract][Full Text] [Related]
5. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.
Orben F; Lankes K; Schneeweis C; Hassan Z; Jakubowsky H; Krauß L; Boniolo F; Schneider C; Schäfer A; Murr J; Schlag C; Kong B; Öllinger R; Wang C; Beyer G; Mahajan UM; Xue Y; Mayerle J; Schmid RM; Kuster B; Rad R; Braun CJ; Wirth M; Reichert M; Saur D; Schneider G
JCI Insight; 2022 May; 7(10):. PubMed ID: 35439169
[TBL] [Abstract][Full Text] [Related]
7. Concepts to Target MYC in Pancreatic Cancer.
Wirth M; Mahboobi S; Krämer OH; Schneider G
Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
[TBL] [Abstract][Full Text] [Related]
8. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice.
Jiang SH; Li J; Dong FY; Yang JY; Liu DJ; Yang XM; Wang YH; Yang MW; Fu XL; Zhang XX; Li Q; Pang XF; Huo YM; Li J; Zhang JF; Lee HY; Lee SJ; Qin WX; Gu JR; Sun YW; Zhang ZG
Gastroenterology; 2017 Jul; 153(1):277-291.e19. PubMed ID: 28315323
[TBL] [Abstract][Full Text] [Related]
9. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
Fang R; Zhang B; Lu X; Jin X; Liu T
J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
[TBL] [Abstract][Full Text] [Related]
10. Proteostasis Dysregulation in Pancreatic Cancer.
Arpalahti L; Haglund C; Holmberg CI
Adv Exp Med Biol; 2020; 1233():101-115. PubMed ID: 32274754
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
Du R; Sullivan DK; Azizian NG; Liu Y; Li Y
BMC Cancer; 2021 Mar; 21(1):237. PubMed ID: 33676427
[TBL] [Abstract][Full Text] [Related]
12. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells.
Bakke J; Wright WC; Zamora AE; Oladimeji P; Crawford JC; Brewer CT; Autry RJ; Evans WE; Thomas PG; Chen T
BMC Cancer; 2019 Mar; 19(1):253. PubMed ID: 30898113
[TBL] [Abstract][Full Text] [Related]
14. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer.
Ni XG; Zhou L; Wang GQ; Liu SM; Bai XF; Liu F; Peppelenbosch MP; Zhao P
Mol Med; 2008; 14(9-10):582-9. PubMed ID: 18584046
[TBL] [Abstract][Full Text] [Related]
15. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.
Dey S; Kwon JJ; Liu S; Hodge GA; Taleb S; Zimmers TA; Wan J; Kota J
Mol Cancer Res; 2020 Feb; 18(2):311-323. PubMed ID: 31662451
[TBL] [Abstract][Full Text] [Related]
16. LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription.
Peng WX; He RZ; Zhang Z; Yang L; Mo YY
Oncogene; 2019 Oct; 38(41):6770-6780. PubMed ID: 31391552
[TBL] [Abstract][Full Text] [Related]
17. POH1 facilitates pancreatic carcinogenesis through MYC-driven acinar-to-ductal metaplasia and is a potential therapeutic target.
Jing T; Xu X; Wu C; Wei D; Yuan L; Huang Y; Liu Y; Wang B
Cancer Lett; 2023 Nov; 577():216444. PubMed ID: 37844756
[TBL] [Abstract][Full Text] [Related]
18. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
19. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
[TBL] [Abstract][Full Text] [Related]
20. Novel c-Myc-Targeting Compound
Sriratanasak N; Petsri K; Laobuthee A; Wattanathana W; Vinayanuwattikun C; Luanpitpong S; Chanvorachote P
Mol Pharmacol; 2020 Aug; 98(2):130-142. PubMed ID: 32487733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]